Patent · US Active

Anti-CD40 antibodies for use in prevention of graft rejection

US11780927B2 · kind B2 · utility

0Cited by

2References

4Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Pascal ESPIE · Village-Neuf, FR
Boerje HARALDSSON · Basel, CH
James RUSH · Thalwil, CH

Key dates

Filing date	Apr 11, 2019
Grant date	Oct 10, 2023
Priority date	—
Expiry date	Oct 17, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure relates to methods, treatment regimens, uses, kits and therapies for preventing graft rejection in solid organ transplantation, by employing anti-CD40 antibodies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.